ENGN · enGene Therapeutics Inc.
$1.79
+0.02 (+1.13%)
At close · Aug 21
Market Cap
$118.57M
Shares
66.99M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.77
Open$1.84
Day$1.76–1.85
52W close$1.44–12.17
Avg vol 30d750K
Short int1.7M · 2.6% float · 2.6d
Short vol40%
DataFeb 2022–Aug 2026
Filing10-Q · Jun 15
Up next
FQ4-26 quarter ends
~Oct 31, 2026
Est
filed Jun 15, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−70%
below
Price vs 50-day avg
−1%
below
RSI (14)
47
neutral
MACD trend
Positive
52-week position
3%
near low
Momentum
relative strength
1-month return
−6%
trailing
6-month return
−82%
trailing
YTD return
−80%
this year
Relative strength
−94%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
+15% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.59% of float · ▲ +5.7% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
70 holders — near 2-yr high, broad support
Squeeze score
50
elevated · 0–100
Fundamentals
EPS growth
+57%
Y/Y
Free cash flow
$-100.7M
Balance sheet
$50.2M
net cash
Quant / Vol
risk profile
Volatility
123%
annualized · 1-yr
Max drawdown
−88%
past year
ATR
5.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−70%
Bearish
Price vs 50-day avg
−1%
Neutral
RSI (14)
47
Neutral
MACD trend
Positive
Bullish
52-week position
3%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
+15% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.59% of float · ▲ +5.7% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
70 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $2 · 3%
Range high $12
vs 200-day avg -70%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENGN
this stock
enGene Therapeutics Inc.
|
$118.57M | -80.4% | — | — | 2.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
ARGX
Argenx SE
|
$64.56B | +23.4% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENGN | +4.7% | -6.4% | -82.5% | -1.1% | -80.4% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +6.7% | -9.7% | -93.7% | -3.2% | -92.2% |